A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)

CompletedOBSERVATIONAL
Enrollment

1,524

Participants

Timeline

Start Date

January 5, 2015

Primary Completion Date

August 4, 2017

Study Completion Date

August 4, 2017

Conditions
Urinary Bladder OveractiveOveractive BladderUrinary Bladder DiseasesUrologic Diseases
Interventions
DRUG

mirabegron

oral

DRUG

antimuscarinic medication

oral

Trial Locations (92)

10003

Site US1106, New York

10065

Site US1111, New York

11530

Site US1096, Garden City

12550

Site US1040, Newburgh

12601

Site US1045, Poughkeepsie

14203

Site US1103, Buffalo

19335

Site US1021, Downingtown

21401

Site US1058, Annapolis

23462

Site US1099, Virginia Beach

27609

Site US1060, Raleigh

29588

Site US1004, Myrtle Beach

30067

Site US1009, Marietta

30342

Site US1042, Atlanta

31909

Site US1035, Columbus

33012

Site US1050, Hialeah

33015

Site US1068, Miami

33060

Site US1055, Pompano Beach

33144

Site US1079, Miami

33155

Site US1031, Miami

Site US1032, Miami

Site US1044, Miami

33162

Site US1048, North Miami Beach

33173

Site US1018, Miami

33175

Site US1098, Miami

33185

Site US1075, Miami

34761

Site US1093, Ocoee

35235

Site US1051, Birmingham

35242

Site US1094, Birmingham

35801

Site US1010, Huntsville

36604

Site US1020, Mobile

37040

Site US1015, Clarksville

43026

Site US1007, Hilliard

47304

Site US1097, Muncie

47714

Site US1019, Evansville

47725

Site US1034, Evansville

48212

Site US1062, Hamtramck

51503

Site US1017, Council Bluffs

53566

Site US1071, Monroe

57104

Site US1084, Sioux Falls

60010

Site US1046, Lake Barrington

63042

Site US1047, Hazelwood

63128

Site US1082, St Louis

63141

Site US1105, St Louis

66210

Site US1064, Overland Park

68114

Site US1102, Omaha

68124

Site US1039, Omaha

70503

Site US1077, Lafayette

72205

Site US1114, Little Rock

72212

Site US1061, Little Rock

75093

Site US1012, Plano

76132

Site US1037, Fort Worth

77043

Site US1080, Houston

77055

Site US1067, Houston

77450

Site US1057, Katy

80234

Site US1090, Northglenn

83404

Site US1016, Idaho Falls

85018

Site US1028, Phoenix

85206

Site US1036, Mesa

85395

Site US1006, Goodyear

85715

Site US1100, Tucson

85741

Site US1083, Tucson

87106

Site US1008, Albuquerque

89128

Site US1043, Las Vegas

89146

Site US1052, Las Vegas

92701

Site US1013, Santa Ana

92844

Site US1112, Garden Grove

95817

Site US1104, Sacramento

98104

Site US1086, Seattle

01805

Site US1088, Burlington

02720

Site US1059, Fall River

02472

Site US1076, Watertown

01605

Site US1089, Worcester

08901

Site US1085, New Brunswick

08081

Site US1001, Sicklerville

02914

Site US1070, Providence

T2V 4R6

Site CA1026, Calgary

V3K3P4

Site CA1066, Coquitlam

V8T2CL

Site CA1000, Victoria

L7NV3V2

Site CA1022, Burlington

L7S 1W7

Site CA1029, Burlington

P3E 379

Site CA1005, Greater Sudbury

K7L357

Site CA1072, Kingston

N6A566

Site CA1023, London

L4T 4J2

Site CA1014, Mississauga

L1H 1G4

Site CA1095, Oshawa

L1H1G6

Site CA1025, Oshawa

K1Y4E9

Site CA1065, Ottawa

L4C 1T9

Site CA1101, Richmond Hill

M1R3A6

Site CA1054, Scarborough Village

M2J2K9

Site CA1027, Toronto

M5T2S8

Site CA1092, Toronto

H9R4S3

Site CA1038, Pointe-Claire

All Listed Sponsors
lead

Astellas Scientific & Medical Affairs, Inc.

INDUSTRY

NCT02386072 - A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB) | Biotech Hunter | Biotech Hunter